Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: An update

Surgical Oncology Clinics of North America

Volumn 12, Issue 1, 2003, Pages 193-210

  Bilchik, Anton J ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL TRIAL; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERANCE; HUMAN; LIVER METASTASIS; MOLECULAR BIOLOGY; PATIENT SELECTION; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037267688     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00079-0     Document Type: Review

References (54)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Fong Y, Blumgart LH. Hepatic colorectal metastases: current status of surgical therapy. Oncology 1998;12:1489-98.
3. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
4. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
5. Preketes AP, King J, Caplehorn JR, et al. CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival. Aust N Z J Surg 1994;64:612-4.
6. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastases. Semin Oncol 1999;26:514-23.
7. Buroker T, Kim PN, Groppe C, et al. 5 FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: Southwest Oncology Group study. Cancer 1978;42:1228-33.
8. Grage TB, Vassilopoulos PP, Shingleton WW, et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surgery 1979;86:550-5.
9. Macdonald JS, Kisner DF, Smythe T, et al. 5-fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU. Cancer Treat Rep 1976;60:1597-600.
10. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
11. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
12. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
13. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-54.
14. Kemeny M, Goldberg D, Beatty D, et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986;57:492-8.
15. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65.
16. Martin JK, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990;125:1022-7.
17. Harmantas A, Rotstein LE, Langer B, et al. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma liver metastatic to the liver. Cancer 1996;78:1639-45.
18. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic fluorouridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-95.
19. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998;228:756-62.
20. Tandan VR, Harmantas A, Gallinger S. Long-term survival after hepatic cryosurgery versus surgical resection for metastatic colorectal carcinoma: a critical review of the literature. Can J Surg 1997;40:175-81.
21. Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology 1997;11:947-57.
22. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885-93.
23. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
24. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327-34.
25. Lorenz M, Muller HH. Randomized, multi-center trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-54.
26. Mosseri M, Fingerth J, Varticousky L, et al. In-vitro evidence that myocardial ischemia resulting from 5 fluorouracil of chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53:3028-33.
27. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
28. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-95.
29. Kemeny MM, Adak S, Gray B, et al. Combined modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002:20:1499-1505.
30. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgery and radiofrequency ablation for unresectable hepatic malignancies: a proposed algorithm. Arch Surg 2000;135:657-62.
31. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 2000;230:1-8.
32. Ravikumar TS, Kane R, Cady B, et al. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 1991;126:1520-3.
33. Sarantou T, Bilchik A, Ramming KP. Complications of hepatic cryosurgery. Semin Surg Oncol 1998;14:156-62.
34. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998;43:141-54.
35. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg 1998;228:201-8.
36. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Semin Surg Oncol 1998;14:163-70.
37. Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593-600.
38. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
39. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13.
40. Johnston PG, Fisher ER, Ruckette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
41. Leichman L, Lenz HJ, Leichman CG, et al. Quantification of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers. Eur J Cancer 1995;31:1306-10.
42. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
43. Rougier P, Van Cutsem E, Bajetta E, et al, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-13.
44. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
45. Bathe OF, Franceschi D, Livingstone AS, et al. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999;5:34-40.
46. Bengtsson G, Carlsson G, Hafstrom L. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981;141:586-9.
47. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1986;103:278-84.
48. Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986;162:109-13.
49. Preketes AP, Caplehorn JR, King J, et al. Effect of hepatic artery chemotherapy on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy. World J Surg 1995;19:768-71.
50. Johnston PF, Allegra CJ. Colorectal cancer biology: clinical implications. Semin Oncol 1995;22:418-32.
51. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
52. Link KH, Kornmann M, Butzer U, et al. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 2000;89:288-96.
53. Davies MM, Johnston PG, Kaur S, et al. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 1999;5:325-8.
54. Bilchik AJ, Wood TF, Chawla SP, et al. Systemic irinotecan or floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer 2001;1:36-42.